{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-22-000242","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.993729+00:00","generated_at":"2026-06-25T21:29:09.635218+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Globus Medical Q1 2022 net sales $230.5M, up 1.4% YoY; GAAP EPS $0.37, non-GAAP $0.42","bullets":["Net sales $230.5M, up 1.4% YoY (1.9% constant currency); U.S. spine sales recovered in March.","GAAP net income $38.1M (-16% YoY); GAAP diluted EPS $0.37 vs $0.44 in Q1 2021.","Non-GAAP diluted EPS $0.42 vs $0.49 in Q1 2021, down 13.1% on higher product development and sales costs.","FY 2022 guidance reaffirmed: net sales $1.025B, non-GAAP diluted EPS $2.10.","First Excelsius3D imaging units shipped; Enabling Technologies pipeline strong."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-22-000242","json":"https://secwatch.observer/filing/0001562762-22-000242.json","markdown":"https://secwatch.observer/filing/0001562762-22-000242.md","text":"https://secwatch.observer/filing/0001562762-22-000242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000156276222000242/0001562762-22-000242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000156276222000242/gmed-20220510x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:29:09.635218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}